INGREZZA shows higher treatment persistence than AUSTEDO XR in study
Go back to INGREZZA shows higher treatment persistence than AUSTEDO XR in study| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 159.57 +1.28 (0.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.29 | 52 Week High | $58.46 | |||
| Open | $161.17 | 52 Week Low | $31.25 | |||
| Day High | $161.39 | P/E | N/A | |||
| Day Low | $159.37 | EPS | $-0.69 | |||
| Volume | 191,442 | |||||
